Aquestive Therapeutics, Inc. (AQST) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Aquestive Therapeutics, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AQST
Aquestive Therapeutics, Inc.
$4.61HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MNPR
Monopar Therapeutics Inc.
$79.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AQST vs MNPR
growth of $100 · dividends reinvested · last 7yAQST -16.0% (-2.5%/yr)MNPR -40.9% (-7.2%/yr)AQST compounded faster over this window
AQST MNPR
AQST vs MNPR: by the numbers
- •AQST is the larger company ($578M vs $533M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -144.63% net margin).
Metrics side by side
Valuation
| Metric | AQST | MNPR |
|---|---|---|
| P/S ratio | 10.69 | N/A |
| P/B ratio | N/A | 4.07 |
Profitability
| Metric | AQST | MNPR |
|---|---|---|
| Gross margin | 67.04% | 0.00% |
| Operating margin | -156.36% | 0.00% |
| Net margin | -144.63% | 0.00% |
| ROE | N/A | -13.64% |
| ROIC | -45.62% | -16.89% |
Growth (annualized)
| Metric | AQST | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | -0.58% | N/A |
| Total return CAGR (5Y) | 2.24% | 27.38% |
Frequently asked
- How have AQST and MNPR total returns compared?
- Over the past 5 years, AQST delivered 2.24% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.